Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/34404| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Haslak, Fatih | en_US |
| dc.contributor.author | Oner, Nimet | en_US |
| dc.contributor.author | Elhani, Inès | en_US |
| dc.contributor.author | Hinze, Tanja | en_US |
| dc.contributor.author | Mamutova, Anna | en_US |
| dc.contributor.author | Bourguiba, Rim | en_US |
| dc.contributor.author | Kasap Cuceoglu, Muserref | en_US |
| dc.contributor.author | Pateras, Konstantinos | en_US |
| dc.contributor.author | Aviel, Yonatan Butbul | en_US |
| dc.contributor.author | Delplanque, Marion | en_US |
| dc.contributor.author | Caorsi, Roberta | en_US |
| dc.contributor.author | Šestan, Mario | en_US |
| dc.contributor.author | Bénard, Stéphanie Ducharme | en_US |
| dc.contributor.author | Brunner, Jürgen | en_US |
| dc.contributor.author | El Moussaoui, Majdouline | en_US |
| dc.contributor.author | Kirijas, Meri | en_US |
| dc.contributor.author | Constantin, Tamas | en_US |
| dc.contributor.author | Arenas, Sonia Carriquí | en_US |
| dc.contributor.author | Khellaf, Ghalia | en_US |
| dc.contributor.author | Guliyeva, Vafa | en_US |
| dc.contributor.author | Assalia, Naiera | en_US |
| dc.contributor.author | Backes, Stefan | en_US |
| dc.contributor.author | Sozeri, Betul | en_US |
| dc.contributor.author | Hofer, Michaël | en_US |
| dc.contributor.author | Ayaz, Nuray | en_US |
| dc.contributor.author | Lachmann, Helen | en_US |
| dc.contributor.author | Wittkowski, Helmut | en_US |
| dc.contributor.author | Hentgen, Véronique | en_US |
| dc.date.accessioned | 2025-12-01T13:05:44Z | - |
| dc.date.available | 2025-12-01T13:05:44Z | - |
| dc.date.issued | 2025-09-26 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/34404 | - |
| dc.description.abstract | Although colchicine is the mainstay of familial Mediterranean fever (FMF) treatment, 5-10% of patients are considered to have colchicine resistance (CR). However, there is no globally agreed CR definition or indications for biological disease-modifying anti-rheumatic drugs (bDMARDs). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ Publishing Group Ltd | en_US |
| dc.relation.ispartof | RMD open | en_US |
| dc.subject | amyloidosis | en_US |
| dc.subject | Familial Mediterranean Fever | en_US |
| dc.subject | Biological Therapy | en_US |
| dc.subject | Interleukin 1 Receptor Antagonist Protein | en_US |
| dc.title | Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1136/rmdopen-2025-006097 | - |
| dc.identifier.url | https://syndication.highwire.org/content/doi/10.1136/rmdopen-2025-006097 | - |
| dc.identifier.volume | 11 | - |
| dc.identifier.issue | 3 | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.